Initial Report on Differential Expression of Sprouty Proteins 1 and 2 in Human Epithelial Ovarian Cancer Cell Lines

• Published in: Journal of Oncology 2012-01, Vol.2012 (2012), p.68-76-009
• Main Authors: Moghaddam, Samar Masoumi, Amini, Afshin, Wei, Ai-Qun, Pourgholami, Mohammad Hossein, Morris, David Lawson
• Format: Article
• Language: English
• ISSN: 1687-8450; 1687-8469; 1687-8450
• DOI: 10.1155/2012/373826

Sprouty (Spry) proteins, modulators of receptor tyrosine kinase signaling pathways, have been shown to be deregulated in a variety of pathological conditions including cancer. In the present study we investigated the expression of Spry1 and Spry2 isoforms in a panel of human ovarian cancer cell lines in vitro. Our western blot analysis showed nonuniform patterns of Spry expression in the cancer cells, none of which conformed to the pattern observed in the normal ovarian epithelial cells employed as the control. Among the seven cancer cell lines studied, Spry1 was expressed lower in four cell lines and higher in one as compared with the control. As for Spry2, four cell lines showed lower and two exhibited higher expression. Results from RT-PCR assay raised the possibility that Spry protein levels may not necessarily correspond with its expression at mRNA level. Our immunostaining study revealed that Spry2 was predominantly distributed within the whole cytoplasm in vesicular structures whereas Spry1 was found in both the cytoplasm and nucleus. This might provide clues to further investigation of Spry mode of action and/or function. Collectively, our study unveiled the differential expression of Spry1 and Spry2 proteins in various ovarian cancer cell lines.